This company has been marked as potentially delisted and may not be actively trading. OvaScience (OVAS) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock OVAS vs. SNDX, OPK, WVE, DYN, ETNB, MLYS, COLL, HROW, RCUS, and ELVNShould you be buying OvaScience stock or one of its competitors? The main competitors of OvaScience include Syndax Pharmaceuticals (SNDX), OPKO Health (OPK), Wave Life Sciences (WVE), Dyne Therapeutics (DYN), 89bio (ETNB), Mineralys Therapeutics (MLYS), Collegium Pharmaceutical (COLL), Harrow (HROW), Arcus Biosciences (RCUS), and Enliven Therapeutics (ELVN). These companies are all part of the "medical" sector. OvaScience vs. Syndax Pharmaceuticals OPKO Health Wave Life Sciences Dyne Therapeutics 89bio Mineralys Therapeutics Collegium Pharmaceutical Harrow Arcus Biosciences Enliven Therapeutics OvaScience (NASDAQ:OVAS) and Syndax Pharmaceuticals (NASDAQ:SNDX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, community ranking, profitability, institutional ownership, analyst recommendations, earnings and valuation. Which has higher earnings and valuation, OVAS or SNDX? OvaScience has higher earnings, but lower revenue than Syndax Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOvaScience$290K958.76-$50.97MN/AN/ASyndax Pharmaceuticals$23.68M48.44-$209.36M-$3.73-3.57 Does the MarketBeat Community prefer OVAS or SNDX? Syndax Pharmaceuticals received 117 more outperform votes than OvaScience when rated by MarketBeat users. Likewise, 65.38% of users gave Syndax Pharmaceuticals an outperform vote while only 63.87% of users gave OvaScience an outperform vote. CompanyUnderperformOutperformOvaScienceOutperform Votes27463.87% Underperform Votes15536.13% Syndax PharmaceuticalsOutperform Votes39165.38% Underperform Votes20734.62% Do institutionals & insiders have more ownership in OVAS or SNDX? 22.5% of OvaScience shares are held by institutional investors. 7.4% of OvaScience shares are held by company insiders. Comparatively, 4.1% of Syndax Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has more volatility & risk, OVAS or SNDX? OvaScience has a beta of 3.11, indicating that its stock price is 211% more volatile than the S&P 500. Comparatively, Syndax Pharmaceuticals has a beta of 1.28, indicating that its stock price is 28% more volatile than the S&P 500. Does the media prefer OVAS or SNDX? In the previous week, Syndax Pharmaceuticals had 7 more articles in the media than OvaScience. MarketBeat recorded 7 mentions for Syndax Pharmaceuticals and 0 mentions for OvaScience. Syndax Pharmaceuticals' average media sentiment score of 1.50 beat OvaScience's score of 0.00 indicating that Syndax Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment OvaScience Neutral Syndax Pharmaceuticals Positive Is OVAS or SNDX more profitable? Syndax Pharmaceuticals has a net margin of 0.00% compared to OvaScience's net margin of -10,128.37%. OvaScience's return on equity of -47.06% beat Syndax Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets OvaScience-10,128.37% -47.06% -42.39% Syndax Pharmaceuticals N/A -64.34%-57.72% Do analysts rate OVAS or SNDX? Syndax Pharmaceuticals has a consensus target price of $36.20, indicating a potential upside of 171.57%. Given Syndax Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Syndax Pharmaceuticals is more favorable than OvaScience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score OvaScience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Syndax Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.90 SummarySyndax Pharmaceuticals beats OvaScience on 9 of the 16 factors compared between the two stocks. Get OvaScience News Delivered to You Automatically Sign up to receive the latest news and ratings for OVAS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OVAS vs. The Competition Export to ExcelMetricOvaSciencePharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$278.04M$6.71B$5.47B$7.82BDividend YieldN/A3.17%5.43%4.29%P/E RatioN/A7.2322.3918.43Price / Sales958.76239.71391.41101.46Price / CashN/A65.8538.1834.62Price / Book4.316.306.684.19Net Income-$50.97M$143.17M$3.22B$248.05M OvaScience Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OVASOvaScienceN/A$7.76-3.6%N/A+131.3%$278.04M$290,000.000.00N/AGap DownSNDXSyndax Pharmaceuticals3.4951 of 5 stars$11.33+0.8%$36.20+219.5%-35.2%$974.88M$23.68M-3.12110Positive NewsOPKOPKO Health4.4536 of 5 stars$1.44+1.4%$2.75+91.0%+15.6%$967.03M$713.14M-7.583,930Upcoming EarningsAnalyst ForecastShort Interest ↓News CoverageWVEWave Life Sciences4.2991 of 5 stars$6.28+4.7%$22.18+253.2%+42.0%$963.89M$108.30M-5.66240Positive NewsDYNDyne Therapeutics3.2611 of 5 stars$7.85+5.1%$47.46+504.6%-53.3%$888MN/A-2.21100Upcoming EarningsShort Interest ↑News CoverageGap DownETNB89bio2.8195 of 5 stars$6.05+2.2%$27.56+355.5%-15.9%$883.20MN/A-2.0840Analyst ForecastOptions VolumePositive NewsMLYSMineralys Therapeutics2.4413 of 5 stars$13.88-0.3%$33.00+137.8%+20.8%$871.46MN/A-3.8128Short Interest ↑COLLCollegium Pharmaceutical3.8875 of 5 stars$27.12+1.5%$43.60+60.8%-25.3%$871.42M$631.45M11.69210Positive NewsHROWHarrow2.6159 of 5 stars$23.79-2.5%$60.50+154.3%+155.5%$848.21M$199.61M-25.31182Positive NewsRCUSArcus Biosciences2.1266 of 5 stars$8.00+4.2%$30.25+277.9%-43.7%$841.53M$258M-2.54500Analyst ForecastPositive NewsGap DownELVNEnliven Therapeutics1.9513 of 5 stars$17.05-0.8%$40.33+136.6%+8.5%$835.52MN/A-8.9750Positive NewsGap Down Related Companies and Tools Related Companies SNDX Competitors OPK Competitors WVE Competitors DYN Competitors ETNB Competitors MLYS Competitors COLL Competitors HROW Competitors RCUS Competitors ELVN Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OVAS) was last updated on 4/26/2025 by MarketBeat.com Staff From Our PartnersTrump’s tariffs just split the AI market in twoTrump’s tariff just split the AI market – among others – in two. One group of AI companies—the ones relying...Traders Agency | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored"I'm risking my reputation on this"I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAII predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OvaScience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share OvaScience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy OVAS Stock Free OVAS Stock Alerts